Fierce Biotech Layoff Tracker: Novartis, bluebird add to pile of 30-plus biotechs laying off staff Horizon BCBS sues Regeneron over Eylea 'kickback' scheme FDA clears Baxter's in-hospital dialysis machine, cementing emergency COVID authorization FDA oncology chief aims to open up accelerated approval for earlier cancer treatment under 'Project FrontRunner' Novartis scores accelerated FDA nod for Vijoice to treat rare overgrowth condition Sanofi cuts 2 dozen Kadmon staffers after $1.9B buyout Gilead unveils pediatric drug development center in Ireland with 33 new jobs GAO confirms questionable Trump-era celeb campaign ad spend Optum, Change Healthcare extend merger agreement as they gear up to fight DOJ suit 20 years in, Genentech persists and perseveres in Alzheimer's with gantenerumab Valo Health nabs TARA Biosystems and its beating heart-on-a-chip Biden orders HHS to strengthen long COVID research, care, coverage and protections Boston Scientific bids farewell to MedSurg, endoscopy president after 30-plus years Salix: Half of IBS, chronic constipation patients lately find their condition ‘more challenging to manage’ Featured Story | By Annalee Armstrong Layoffs are hitting biotech fast and furious. The Fierce Biotech Layoff Tracker is listing them all from Jan. 1 on. read more |
| |
|---|
|
Top Stories By Paige Minemyer Horizon Blue Cross Blue Shield of New Jersey has filed suit against Regeneron Pharmaceuticals charging the company has paid "kickbacks" to a charity in order to boost sales of its Eylea drug. read more By Andrea Park The system was initially granted the FDA’s emergency OK within the first few months of the COVID pandemic. read more By Angus Liu For decades, the FDA has been offering accelerated approvals to open early access to new cancer drugs, but mostly for patients who've already tried several other regimens. FDA oncology chief Richard Pazdur, M.D., now plans to disrupt that longstanding practice and bring quick approvals to early treatment. read more By Kevin Dunleavy Less than three years after launching a budding blockbuster in breast cancer drug Piqray (alpelisib), Novartis has scored an approval to treat PIK3CA-related overgrowth spectrum (PROS), a rare condition that causes blood vessel abnormalities and overgrowth of tissue that can present in a variety of ways. read more By Eric Sagonowsky Looking to bolster Sanofi's portfolio of marketed drugs and pipeline prospects, CEO Paul Hudson went on a dealmaking spree last year. That included the drugmaker's $1.9 billion buyout of Kadmon, where more than two dozen staffers are now losing their jobs. read more By Gabrielle Masson Gilead has unveiled a new global pediatric drug development center in Ireland, which will have 33 job openings by the end of 2022. read more By Natalie Missakian The Trump administration used taxpayer money to pay a contractor with ties to a senior health department official to plan a star-studded COVID-19 ad campaign before the 2020 election, and initially vetted the participating celebrities based on their politics, a new report by the Government Accountability Office confirms. read more By Paige Minemyer UnitedHealth Group's Optum and Change Healthcare have further extended their merger agreement to Dec. 31. The extension comes ahead of a two-week trial to determine the deal's fate. read more By Annalee Armstrong Genentech has been working on gantenerumab for 20 years, and, while it's tempting to try to rush the clinical process, the Roche unit is slowly but surely following the evidence. read more By Conor Hale TARA’s “heart-on-a-chip” system creates a small, working simulacrum of the beating organ to help researchers predict the success of potential therapies. read more By Dave Muoio The White House's long COVID directives include targeted education for providers, further exploration of health insurance coverage, disability protections and more. read more By Andrea Park This summer, Boston Scientific will lose one of its longest-serving executives as David Pierce heads into retirement after spending his entire career with the medtech giant. read more By Ben Adams Patients with common but deeply uncomfortable gastrointestinal issues are still struggling to manage their conditions. A Salix-sponsored survey found patients with IBS or chronic constipation saw symptoms worsen—and for some of them, begin—during the pandemic. read more |
